4 chloro 3 methyl phenol  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Name:
    Chloro 5 methoxy 2 1 4 methoxyphenyl imino N ethyl phenyl C 1 2 3 4 5 pentamethylcyclopentadienyl iridium III
    Description:
    Sigma Life Science is committed to bringing you Greener Alternative Products which adhere to one or more of The 12 Principles of Greener Chemistry This product has been enhanced for energy efficiency Find details here
    Catalog Number:
    767727
    Price:
    None
    Applications:
    Catalyst for reductive amination by transfer hydrogenation.
    Buy from Supplier


    Structured Review

    Millipore 4 chloro 3 methyl phenol
    Chloro 5 methoxy 2 1 4 methoxyphenyl imino N ethyl phenyl C 1 2 3 4 5 pentamethylcyclopentadienyl iridium III
    Sigma Life Science is committed to bringing you Greener Alternative Products which adhere to one or more of The 12 Principles of Greener Chemistry This product has been enhanced for energy efficiency Find details here
    https://www.bioz.com/result/4 chloro 3 methyl phenol/product/Millipore
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    4 chloro 3 methyl phenol - by Bioz Stars, 2020-09
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Chlorocatechols Substituted at Positions 4 and 5 Are Substrates of the Broad-Spectrum Chlorocatechol 1,2-Dioxygenase of Pseudomonas chlororaphis RW71
    Article Snippet: Tetrachlorocatechol and 3,4,5-trichlorocatechol were purchased from Aldrich (Steinheim, Germany) and Promochem (Wesel, Germany), respectively.

    Article Title: Effect of Parameters on Oxychlorination of Tert-Butyl Ethers
    Article Snippet: EXPERIMENTAL MTBE 98%, 1,2-dichloro-2-methylpropane, 3-chloro-2-chloromethylpropene (Sigma-Aldrich Germany), ETBE (Polish Petrol Concern Orlen” S.A. Płock Poland), tert -butyl alcohol, hydrochloric acid 36%, nitric acid (V) 65%, hydrogen peroxide 30%, and sodium chloride (Polish Chemical Reagents) were used in our studies.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96
    Millipore lapatinib
    Combination <t>lapatinib</t> and docetaxel studies in mice
    Lapatinib, supplied by Millipore, used in various techniques. Bioz Stars score: 96/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lapatinib/product/Millipore
    Average 96 stars, based on 11 article reviews
    Price from $9.99 to $1999.99
    lapatinib - by Bioz Stars, 2020-09
    96/100 stars
      Buy from Supplier

    96
    Millipore pyronaridine tetraphosphate
    Combination data for the <t>pyronaridine</t> and artesunate checkerboard assay in HeLa cells. A) Inhibition/cytotoxicity plots for the pyronaridine and artesunate controls (compound tested in the absence of the other compound). Controls were run in triplicate at 5 concentrations per plate, so the total number from replicates for each compound varied (Pyronaridine, n=27; Artesunate, n=18). Error bars represent the SEM at each concentration tested. B) Graphical representations (from left to right) of the inhibition plots of the smoothed raw data, predicted additive inhibition and predicted inhibition using the 7-parameter BRAID analysis. It is noted that inhibition data under toxic concentrations ( > 50% cell death) were removed from the analysis. The “Additive” or “BRAID” error represents the corresponding accuracy of fit with the “Observed Effect”. κ represents the combinatory effect where κ = 0 implies additivity, and κ > 0 implies synergy, “strong synergy” corresponds to κ = 2.5, “mild synergy” corresponds to κ = 1, “mild antagonism” corresponds to κ = −0.66, and “strong antagonism” corresponds to κ = −1. C) Representation of the cytotoxicity (toxicity is representative of % cell death from control) arranged in the same manner as inhibition.
    Pyronaridine Tetraphosphate, supplied by Millipore, used in various techniques. Bioz Stars score: 96/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyronaridine tetraphosphate/product/Millipore
    Average 96 stars, based on 9 article reviews
    Price from $9.99 to $1999.99
    pyronaridine tetraphosphate - by Bioz Stars, 2020-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    Combination lapatinib and docetaxel studies in mice

    Journal: Anti-cancer drugs

    Article Title: Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

    doi: 10.1097/CAD.0b013e3283645e1a

    Figure Lengend Snippet: Combination lapatinib and docetaxel studies in mice

    Article Snippet: Lapatinib was formulated as a suspension of 12mg/ml in 0.5% hydroxypropyl methylcellulose: 0.1% Tween 80 in Milli-Q water (Millipore, Billerica, Massachusetts, USA) and administered through an intraperitoneal injection as a bolus dose of 60 mg/kg.

    Techniques: Mouse Assay

    Combination lapatinib and doxorubicin studies in mice

    Journal: Anti-cancer drugs

    Article Title: Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

    doi: 10.1097/CAD.0b013e3283645e1a

    Figure Lengend Snippet: Combination lapatinib and doxorubicin studies in mice

    Article Snippet: Lapatinib was formulated as a suspension of 12mg/ml in 0.5% hydroxypropyl methylcellulose: 0.1% Tween 80 in Milli-Q water (Millipore, Billerica, Massachusetts, USA) and administered through an intraperitoneal injection as a bolus dose of 60 mg/kg.

    Techniques: Mouse Assay

    Lapatinib concentrations in mouse plasma. (a) Time course of maximum and minimum lapatinib concentrations after five 60 mg/kg intraperitoneal doses (at times 0, 3, 6, 9, and 12 h). Maximum and minimum concentrations were achieved 1 and 3 h after dose,

    Journal: Anti-cancer drugs

    Article Title: Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

    doi: 10.1097/CAD.0b013e3283645e1a

    Figure Lengend Snippet: Lapatinib concentrations in mouse plasma. (a) Time course of maximum and minimum lapatinib concentrations after five 60 mg/kg intraperitoneal doses (at times 0, 3, 6, 9, and 12 h). Maximum and minimum concentrations were achieved 1 and 3 h after dose,

    Article Snippet: Lapatinib was formulated as a suspension of 12mg/ml in 0.5% hydroxypropyl methylcellulose: 0.1% Tween 80 in Milli-Q water (Millipore, Billerica, Massachusetts, USA) and administered through an intraperitoneal injection as a bolus dose of 60 mg/kg.

    Techniques:

    (a–i) Time courses of docetaxel concentrations in mouse plasma and tissues after a single dose of 3 mg/kg intravenous docetaxel administered at time 0 h. For the single-dose lapatinib study, 1 h before docetaxel administration (at time –

    Journal: Anti-cancer drugs

    Article Title: Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

    doi: 10.1097/CAD.0b013e3283645e1a

    Figure Lengend Snippet: (a–i) Time courses of docetaxel concentrations in mouse plasma and tissues after a single dose of 3 mg/kg intravenous docetaxel administered at time 0 h. For the single-dose lapatinib study, 1 h before docetaxel administration (at time –

    Article Snippet: Lapatinib was formulated as a suspension of 12mg/ml in 0.5% hydroxypropyl methylcellulose: 0.1% Tween 80 in Milli-Q water (Millipore, Billerica, Massachusetts, USA) and administered through an intraperitoneal injection as a bolus dose of 60 mg/kg.

    Techniques:

    (a–g) Time courses of doxorubicin concentrations in mouse plasma and tissues after a single dose of 6 mg/kg intravenous doxorubicin administered at time 0 h. For the single-dose lapatinib study, 1 h before doxorubicin administration (at time –

    Journal: Anti-cancer drugs

    Article Title: Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

    doi: 10.1097/CAD.0b013e3283645e1a

    Figure Lengend Snippet: (a–g) Time courses of doxorubicin concentrations in mouse plasma and tissues after a single dose of 6 mg/kg intravenous doxorubicin administered at time 0 h. For the single-dose lapatinib study, 1 h before doxorubicin administration (at time –

    Article Snippet: Lapatinib was formulated as a suspension of 12mg/ml in 0.5% hydroxypropyl methylcellulose: 0.1% Tween 80 in Milli-Q water (Millipore, Billerica, Massachusetts, USA) and administered through an intraperitoneal injection as a bolus dose of 60 mg/kg.

    Techniques:

    Combination lapatinib and chemotherapy clinical trials

    Journal: Anti-cancer drugs

    Article Title: Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

    doi: 10.1097/CAD.0b013e3283645e1a

    Figure Lengend Snippet: Combination lapatinib and chemotherapy clinical trials

    Article Snippet: Lapatinib was formulated as a suspension of 12mg/ml in 0.5% hydroxypropyl methylcellulose: 0.1% Tween 80 in Milli-Q water (Millipore, Billerica, Massachusetts, USA) and administered through an intraperitoneal injection as a bolus dose of 60 mg/kg.

    Techniques:

    The combination of Notch and ErbB1/2 receptor inhibition reduces acinar size and mammosphere formation regardless of ErbB2 status. MCF10DCIS.com and SUM225 cells were treated with control, DAPT, lapatinib or combination (comb) in (A) matrigel culture and (B) mammosphere culture. (A) Cells were treated from day 0 and media/inhibitor were changed every 3 days. After 21 days in culture the sizes of the acini were measured ( µm).(B) Mammosphere-forming efficiency (MFE) was calculated by dividing the number of mammospheres formed by the original number of cells seeded and is expressed as a percentage compared to control. Mean±standard error of 3 independent experiments, Man Witney U test, two-tailed, NSD – No significant difference.

    Journal: PLoS ONE

    Article Title: Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status

    doi: 10.1371/journal.pone.0056840

    Figure Lengend Snippet: The combination of Notch and ErbB1/2 receptor inhibition reduces acinar size and mammosphere formation regardless of ErbB2 status. MCF10DCIS.com and SUM225 cells were treated with control, DAPT, lapatinib or combination (comb) in (A) matrigel culture and (B) mammosphere culture. (A) Cells were treated from day 0 and media/inhibitor were changed every 3 days. After 21 days in culture the sizes of the acini were measured ( µm).(B) Mammosphere-forming efficiency (MFE) was calculated by dividing the number of mammospheres formed by the original number of cells seeded and is expressed as a percentage compared to control. Mean±standard error of 3 independent experiments, Man Witney U test, two-tailed, NSD – No significant difference.

    Article Snippet: Calbiochem) and lapatinib (a HER2/EGFR tyrosine kinase inhibitor) using DMSO control.

    Techniques: Inhibition, Two Tailed Test

    Notch and ErbB1/2 receptor inhibition reduces the size of DCIS cell line acini. MCF10DCIS.com and SUM225 cells were grown in matrigel culture in the presence or absence of DAPT 5 and 10 µM (A), Lapatinib 0.05 and 0.1 µM (B). Cells were treated from day 0 and media/inhibitor was changed every 3 days. After 21 days in culture the size of the acini were measured (µm). (C) Bright field images of DCIS acini grown in the presence or absence of DAPT 5 and 20 µM or Lapatinib 0.05-and 0.1 µM. Scale bar represent 100 µm, graphs represent mean±standard error of 3 independent experiments, Man Witney U test, two-tailed, * p≤0.032, ** p≤0.008, *** p≤0.0001.

    Journal: PLoS ONE

    Article Title: Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status

    doi: 10.1371/journal.pone.0056840

    Figure Lengend Snippet: Notch and ErbB1/2 receptor inhibition reduces the size of DCIS cell line acini. MCF10DCIS.com and SUM225 cells were grown in matrigel culture in the presence or absence of DAPT 5 and 10 µM (A), Lapatinib 0.05 and 0.1 µM (B). Cells were treated from day 0 and media/inhibitor was changed every 3 days. After 21 days in culture the size of the acini were measured (µm). (C) Bright field images of DCIS acini grown in the presence or absence of DAPT 5 and 20 µM or Lapatinib 0.05-and 0.1 µM. Scale bar represent 100 µm, graphs represent mean±standard error of 3 independent experiments, Man Witney U test, two-tailed, * p≤0.032, ** p≤0.008, *** p≤0.0001.

    Article Snippet: Calbiochem) and lapatinib (a HER2/EGFR tyrosine kinase inhibitor) using DMSO control.

    Techniques: Inhibition, Two Tailed Test

    Notch and ErbB1/2 receptor inhibition reduces mammosphere forming efficiency. MCF10DCIS.com and SUM-225 cells were treated with DAPT 1–10 µM (A) or Lapatinib 0.25–2.5 µM (B) in mammosphere culture. Mammosphere-forming efficiency (MFE) was calculated by dividing the number of mammospheres formed by the original number of cells seeded and is expressed as a percentage compared to control. Mean±standard error n = 3, Man Witney U test, two-tailed, * p

    Journal: PLoS ONE

    Article Title: Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status

    doi: 10.1371/journal.pone.0056840

    Figure Lengend Snippet: Notch and ErbB1/2 receptor inhibition reduces mammosphere forming efficiency. MCF10DCIS.com and SUM-225 cells were treated with DAPT 1–10 µM (A) or Lapatinib 0.25–2.5 µM (B) in mammosphere culture. Mammosphere-forming efficiency (MFE) was calculated by dividing the number of mammospheres formed by the original number of cells seeded and is expressed as a percentage compared to control. Mean±standard error n = 3, Man Witney U test, two-tailed, * p

    Article Snippet: Calbiochem) and lapatinib (a HER2/EGFR tyrosine kinase inhibitor) using DMSO control.

    Techniques: Inhibition, Two Tailed Test

    Downstream signalling in DCIS cell line mammospheres. Western blot analysis of downstream targets of Notch and ErbB1/2 receptor signalling in (A) MCF10DCIS.com and (B) SUM225 cells after treatment with DAPT or Lapatinib for 7 days in non-adherent mammosphere culture. Treatments were added at time zero. pAKT = phospho-AKT; AKT = total AKT; pMAPK = phospho-MAPK; MAPK = total MAPK; NICD = Notch1 intracellular domain. β-actin was used as a loading control.

    Journal: PLoS ONE

    Article Title: Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status

    doi: 10.1371/journal.pone.0056840

    Figure Lengend Snippet: Downstream signalling in DCIS cell line mammospheres. Western blot analysis of downstream targets of Notch and ErbB1/2 receptor signalling in (A) MCF10DCIS.com and (B) SUM225 cells after treatment with DAPT or Lapatinib for 7 days in non-adherent mammosphere culture. Treatments were added at time zero. pAKT = phospho-AKT; AKT = total AKT; pMAPK = phospho-MAPK; MAPK = total MAPK; NICD = Notch1 intracellular domain. β-actin was used as a loading control.

    Article Snippet: Calbiochem) and lapatinib (a HER2/EGFR tyrosine kinase inhibitor) using DMSO control.

    Techniques: Western Blot

    In H2228, apoptosis is increased by the combined treatment with ALK inhibitors and gefitinib or lapatinib. ( a ) H2228 cells were treated in 0.05% FCS with CEP-14083 or CEP-28122 (300 nℳ), and gefinitib (G; 1 μℳ) as single agent or in combination. Apoptosis was measured by tetrametylrodamine methyl ester (TMRM) staining and fluorescence-activated cell sorting (FACS) analysis at the indicated tome points. *Significance is referred to the corresponding single-agent treatment. ( b ) H2228 cells were treated with CEP-28122 alone or in combination with lapatinib (L) or gefitinib (G) in 0.05% FCS for 24 h. Total cell lysates were blotted with the indicated antibodies. ( c ) H2228 cells were treated with CEP-28122 alone or in combination with lapatinib in 0.05% FCS. TMRM staining followed by FACS analysis was performed at indicated times of treatment to check the percentage of apoptotic cells. ( d ) Primary ALK+ NSCLC were stained with anti-ERBB2 or anti-ALK antibodies. Shown are two representative cases.

    Journal: Oncogenesis

    Article Title: The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1

    doi: 10.1038/oncsis.2013.7

    Figure Lengend Snippet: In H2228, apoptosis is increased by the combined treatment with ALK inhibitors and gefitinib or lapatinib. ( a ) H2228 cells were treated in 0.05% FCS with CEP-14083 or CEP-28122 (300 nℳ), and gefinitib (G; 1 μℳ) as single agent or in combination. Apoptosis was measured by tetrametylrodamine methyl ester (TMRM) staining and fluorescence-activated cell sorting (FACS) analysis at the indicated tome points. *Significance is referred to the corresponding single-agent treatment. ( b ) H2228 cells were treated with CEP-28122 alone or in combination with lapatinib (L) or gefitinib (G) in 0.05% FCS for 24 h. Total cell lysates were blotted with the indicated antibodies. ( c ) H2228 cells were treated with CEP-28122 alone or in combination with lapatinib in 0.05% FCS. TMRM staining followed by FACS analysis was performed at indicated times of treatment to check the percentage of apoptotic cells. ( d ) Primary ALK+ NSCLC were stained with anti-ERBB2 or anti-ALK antibodies. Shown are two representative cases.

    Article Snippet: ALK inhibitors, CEP-14083, CEP-26939 and CEP-28122 (Cephalon), were used at 300 nℳ/l; gefitinib (ZD1839, Iressa) at 1 μℳ/l; lapatinib at 2 μℳ/l; Src kinase inhibitor-1 (Calbiochem, Millipore Corporation, Billerica, MA, USA) at 5 μℳ/l; and PHA-665752 (Met inhibitor) at 250 nℳ.

    Techniques: Staining, Fluorescence, FACS

    EGF or Heregulin stimulation rescues ALK-treated NSCLC cells through Erk1/2 and AKT. ( a ) Cell viability of treated H2228 and H3122 cells with or without EGF stimulation (10 ng/ml) was evaluated with Cell Titer-Glo Luminescent cell viability assay at the indicated time points. Significances * and ** is referred to the corresponding single-agent treatment. ( b ) H2228 and H3122 cells were treated for 6 h with 300 nℳ CEP-28122, alone or in combination with 1 μℳ gefitinib (G) in 0.05% FCS. Cells were stimulated with EGF (10 ng/ml) for 15 min and then collected. Total cell lysates were blotted with the indicated antibodies. ( c , d ) H2228 cells were treated with CEP-28122 alone or combined with gefitinib or lapatinib for 24 h, and with or without Heregulin (HRG) stimulation (50 ng/μl) for 30 min and then collected. Total cell lysates were blotted with the indicated antibodies ( c ). Cell viability was evaluated as previously described at the indicated time points. Significance according to Student's t -test corresponded to * P

    Journal: Oncogenesis

    Article Title: The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1

    doi: 10.1038/oncsis.2013.7

    Figure Lengend Snippet: EGF or Heregulin stimulation rescues ALK-treated NSCLC cells through Erk1/2 and AKT. ( a ) Cell viability of treated H2228 and H3122 cells with or without EGF stimulation (10 ng/ml) was evaluated with Cell Titer-Glo Luminescent cell viability assay at the indicated time points. Significances * and ** is referred to the corresponding single-agent treatment. ( b ) H2228 and H3122 cells were treated for 6 h with 300 nℳ CEP-28122, alone or in combination with 1 μℳ gefitinib (G) in 0.05% FCS. Cells were stimulated with EGF (10 ng/ml) for 15 min and then collected. Total cell lysates were blotted with the indicated antibodies. ( c , d ) H2228 cells were treated with CEP-28122 alone or combined with gefitinib or lapatinib for 24 h, and with or without Heregulin (HRG) stimulation (50 ng/μl) for 30 min and then collected. Total cell lysates were blotted with the indicated antibodies ( c ). Cell viability was evaluated as previously described at the indicated time points. Significance according to Student's t -test corresponded to * P

    Article Snippet: ALK inhibitors, CEP-14083, CEP-26939 and CEP-28122 (Cephalon), were used at 300 nℳ/l; gefitinib (ZD1839, Iressa) at 1 μℳ/l; lapatinib at 2 μℳ/l; Src kinase inhibitor-1 (Calbiochem, Millipore Corporation, Billerica, MA, USA) at 5 μℳ/l; and PHA-665752 (Met inhibitor) at 250 nℳ.

    Techniques: Cell Viability Assay

    Combination data for the pyronaridine and artesunate checkerboard assay in HeLa cells. A) Inhibition/cytotoxicity plots for the pyronaridine and artesunate controls (compound tested in the absence of the other compound). Controls were run in triplicate at 5 concentrations per plate, so the total number from replicates for each compound varied (Pyronaridine, n=27; Artesunate, n=18). Error bars represent the SEM at each concentration tested. B) Graphical representations (from left to right) of the inhibition plots of the smoothed raw data, predicted additive inhibition and predicted inhibition using the 7-parameter BRAID analysis. It is noted that inhibition data under toxic concentrations ( > 50% cell death) were removed from the analysis. The “Additive” or “BRAID” error represents the corresponding accuracy of fit with the “Observed Effect”. κ represents the combinatory effect where κ = 0 implies additivity, and κ > 0 implies synergy, “strong synergy” corresponds to κ = 2.5, “mild synergy” corresponds to κ = 1, “mild antagonism” corresponds to κ = −0.66, and “strong antagonism” corresponds to κ = −1. C) Representation of the cytotoxicity (toxicity is representative of % cell death from control) arranged in the same manner as inhibition.

    Journal: Antiviral Research

    Article Title: Repurposing Pyramax®, Quinacrine and Tilorone as Treatments for Ebola Virus Disease

    doi: 10.1016/j.antiviral.2020.104908

    Figure Lengend Snippet: Combination data for the pyronaridine and artesunate checkerboard assay in HeLa cells. A) Inhibition/cytotoxicity plots for the pyronaridine and artesunate controls (compound tested in the absence of the other compound). Controls were run in triplicate at 5 concentrations per plate, so the total number from replicates for each compound varied (Pyronaridine, n=27; Artesunate, n=18). Error bars represent the SEM at each concentration tested. B) Graphical representations (from left to right) of the inhibition plots of the smoothed raw data, predicted additive inhibition and predicted inhibition using the 7-parameter BRAID analysis. It is noted that inhibition data under toxic concentrations ( > 50% cell death) were removed from the analysis. The “Additive” or “BRAID” error represents the corresponding accuracy of fit with the “Observed Effect”. κ represents the combinatory effect where κ = 0 implies additivity, and κ > 0 implies synergy, “strong synergy” corresponds to κ = 2.5, “mild synergy” corresponds to κ = 1, “mild antagonism” corresponds to κ = −0.66, and “strong antagonism” corresponds to κ = −1. C) Representation of the cytotoxicity (toxicity is representative of % cell death from control) arranged in the same manner as inhibition.

    Article Snippet: Pyronaridine tetraphosphate, tilorone and quinacrine were also tested (using the NIAID DMID services) against representatives of several viruses using human cells.

    Techniques: Inhibition, Concentration Assay

    Inhibition analysis of total fluorescent intensity/cell of lysotracker red by chloroquine, pyronaridine and artesunate in MCF7 Cells. Lysotracker accumulation in lysosomes is pH dependent, therefore a reduction in signal from the lysotracker suggests a pH increase in these organelles. This is proposed to be caused by accumulation of the charged base of the lysosomotropic compound in the lysosome, which in a lower pH environment becomes neutralized and trapped in the organelle. A) Representative images showing Lysotracker lysosomal accumulation inhibition at various concentrations. B) Graphical representation and quantification (Parentheses represent 95% CI) of the dose-dependent effect of on Lysotracker accumulation in lysosomes (Error bars represent SEM). Outliers were identified using the ROUT method (Q=10%) and consequentially removed. C) Measure of cellular toxicity at concentrations and times mimicking the inhibition assays.

    Journal: Antiviral Research

    Article Title: Repurposing Pyramax®, Quinacrine and Tilorone as Treatments for Ebola Virus Disease

    doi: 10.1016/j.antiviral.2020.104908

    Figure Lengend Snippet: Inhibition analysis of total fluorescent intensity/cell of lysotracker red by chloroquine, pyronaridine and artesunate in MCF7 Cells. Lysotracker accumulation in lysosomes is pH dependent, therefore a reduction in signal from the lysotracker suggests a pH increase in these organelles. This is proposed to be caused by accumulation of the charged base of the lysosomotropic compound in the lysosome, which in a lower pH environment becomes neutralized and trapped in the organelle. A) Representative images showing Lysotracker lysosomal accumulation inhibition at various concentrations. B) Graphical representation and quantification (Parentheses represent 95% CI) of the dose-dependent effect of on Lysotracker accumulation in lysosomes (Error bars represent SEM). Outliers were identified using the ROUT method (Q=10%) and consequentially removed. C) Measure of cellular toxicity at concentrations and times mimicking the inhibition assays.

    Article Snippet: Pyronaridine tetraphosphate, tilorone and quinacrine were also tested (using the NIAID DMID services) against representatives of several viruses using human cells.

    Techniques: Inhibition